Literature DB >> 17688953

Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?

Elena Gonzalez-Rey1, Mario Delgado.   

Abstract

The loss of immune tolerance results in the breakdown of immune homeostasis and the appearance of exacerbated inflammatory conditions. Some anti-inflammatory neuropeptides have recently emerged as endogenous factors participating in the maintenance of immune tolerance. The effects of these neuropeptides in self-tolerance primarily depend on the activation of cAMP-protein kinase A signaling and the regulation of various transduction pathways involved in the expression of many immune factors. Understanding of the structure-function relationship of anti-inflammatory neuropeptides and their receptors will facilitate the development of novel pharmacological agents for the treatment of immune disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17688953     DOI: 10.1016/j.tips.2007.07.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  15 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

2.  Mechanisms of VIP-induced inhibition of the lymphatic vessel pump.

Authors:  Pierre-Yves von der Weid; Sonia Rehal; Peter Dyrda; Stewart Lee; Ryan Mathias; Mozibur Rahman; Simon Roizes; Mohammad S Imtiaz
Journal:  J Physiol       Date:  2012-03-25       Impact factor: 5.182

Review 3.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

Review 4.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

5.  The neuropeptide cortistatin attenuates experimental autoimmune myocarditis via inhibition of cardiomyogenic T cell-driven inflammatory responses.

Authors:  Virginia Delgado-Maroto; Clara P Falo; Irene Forte-Lago; Norma Adan; Maria Morell; Elena Maganto-Garcia; Gema Robledo; Francisco O'Valle; Andrew H Lichtman; Elena Gonzalez-Rey; Mario Delgado
Journal:  Br J Pharmacol       Date:  2017-01-08       Impact factor: 8.739

6.  Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: involvement of toll-like receptor 4 signaling.

Authors:  Fabricia Petronilho; Francieli Vuolo; Letícia Selinger Galant; Larissa Constantino; Cristiane Damiani Tomasi; Vinicius Renne Giombelli; Cláudio Teodoro de Souza; Sabrina da Silva; Denise Frediani Barbeiro; Francisco Garcia Soriano; Emílio Luiz Streck; Cristiane Ritter; Alfeu Zanotto-Filho; Matheus Augusto Pasquali; Daniel Pens Gelain; José Luiz Rybarczyk-Filho; José Cláudio Fonseca Moreira; Norman L Block; Rafael Roesler; Gilberto Schwartsmann; Andrew V Schally; Felipe Dal-Pizzol
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

Review 7.  Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.

Authors:  Elena Gonzalez-Rey; Doina Ganea; Mario Delgado
Journal:  Curr Opin Pharmacol       Date:  2010-08       Impact factor: 5.547

8.  Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels.

Authors:  Per Anderson; Elena Gonzalez-Rey
Journal:  Mol Cell Biol       Date:  2010-03-15       Impact factor: 4.272

9.  Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions.

Authors:  Brandon S Twardy; Rudragouda Channappanavar; Susmit Suvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-04       Impact factor: 4.799

10.  The melanocortin MC(1) receptor agonist BMS-470539 inhibits leucocyte trafficking in the inflamed vasculature.

Authors:  G Leoni; M-B Voisin; K Carlson; Sj Getting; S Nourshargh; M Perretti
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.